January 25
2021
Anjum Shabbir
share
11th January 2021
Consumer, Health & Environment Covid-19 Institutional law

COVID-19: Action for annulment of Regulation on clinical trials for GMO-containing medicinal products published

Official publication has been made of an action for annulment (T-633/20) brought by several applicants, including the Coordination nationale médicale santé (France), against the European Parliament and Council of the European Union and challenging Regulation 2020/1043 on the conduct of clinical trials with and supply of medicinal products for human use containing or consisting of genetically modified organisms intended to treat or prevent coronavirus disease (COVID-19).

In support of their action, the applicants rely on the following pleas in law:

Based on the consequences and risks that the contested regulation entails, there was no justification for removing all measures for assessing the risks associated with genetically m
×

Your privacy is important for us

We use cookies to improve the user experience. Please review privacy preferences.

Accept all Settings

Check our privacy policy and cookies policy.

Cookies